D&O

Flux Power Reports Fiscal Year 2024 Third Quarter Financial Results

Retrieved on: 
Jeudi, mai 9, 2024

Gross profit for the fiscal third quarter of 2024 decreased 7% to $4.4 million compared to a gross profit of $4.7 million in the fiscal third quarter of 2023.

Key Points: 
  • Gross profit for the fiscal third quarter of 2024 decreased 7% to $4.4 million compared to a gross profit of $4.7 million in the fiscal third quarter of 2023.
  • Gross margin decreased to 30% in the fiscal third quarter of 2024 as compared to 31% in the fiscal third quarter of 2023.
  • Adjusted EBITDA loss was $1.4 million in the fiscal third quarter of 2024 as compared to a loss of $0.7 million in the fiscal third quarter of 2023, primarily attributable to the impact of lower revenue.
  • Flux Power CEO Ron Dutt and CFO Kevin Royal will host the conference call, followed by a question-and-answer session.

Aon Launches Suite of Risk Analyzer Tools to Help Clients Make Better Decisions

Retrieved on: 
Mercredi, mai 1, 2024

CHICAGO, May 1, 2024 /PRNewswire/ -- Aon plc (NYSE: AON) today launched a new suite of risk analyzer tools that allow brokers in North America to exposure data, quantify loss potential and help risk managers make better decisions based on total cost of risk.

Key Points: 
  • CHICAGO, May 1, 2024 /PRNewswire/ -- Aon plc (NYSE: AON) today launched a new suite of risk analyzer tools that allow brokers in North America to exposure data, quantify loss potential and help risk managers make better decisions based on total cost of risk.
  • Aon's Property Risk Analyzer is the latest release under Aon Actionable Analytics, which is how the firm brings together its data, tools and analytics professionals to make better decisions.
  • "Aon's Risk Analyzers expand the risk insights that brokers can provide to  advise clients," said Joe Peiser, CEO of Commercial Risk, Aon.
  • Aon's Property Risk Analyzer allows risk managers quick access to:
    Data quality assessments, which improve model efficacy and consequently price of risk.

Vaxxinity Issues Shareholder Letter

Retrieved on: 
Vendredi, avril 19, 2024

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.

Key Points: 
  • CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
  • Choosing to go public is a path many pursue primarily to obtain access to greater institutional pools of capital.
  • Given these dynamics, after careful consideration, the Board of Directors of Vaxxinity has determined that being a private company will give us significantly more opportunity and flexibility going forward to deliver shareholder value and patient impact.
  • We have shown that Vaxxinity can create vaccines that are as good, if not better, than those already in the market.

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, avril 18, 2024

In 2023, income increased by CHF 0.2 million to CHF 1.6 million compared to CHF 1.4 million in 2022.

Key Points: 
  • In 2023, income increased by CHF 0.2 million to CHF 1.6 million compared to CHF 1.4 million in 2022.
  • R&D expenses decreased by CHF 7.7 million to CHF 7.0 million in 2023 compared to CHF 14.7 million in 2022, primarily due to decreased dipraglurant related external research and development activities.
  • Our net loss decreased by CHF 10.2 million to CHF 10.6 million in 2023 compared to CHF 20.8 million in 2022, primarily due to reduced R&D expenses.
  • Cash and cash equivalents decreased to CHF 3.9 million in 2023, compared to CHF 7.0 million in 2022.

Quadrant Insurance Managers and Verve Risk Services Ltd Announce Exclusive Relationship

Retrieved on: 
Mercredi, mai 1, 2024

Quadrant and Verve are pleased to announce their latest step in advancing a partnership that began over 20 years ago from an underwriting relationship.

Key Points: 
  • Quadrant and Verve are pleased to announce their latest step in advancing a partnership that began over 20 years ago from an underwriting relationship.
  • Quadrant will be the exclusive regional partner for Verve specifically for risks domiciled in NC, MT, TN, & VT by offering insurance company management and professional liability (D&O, EPL, Fiduciary, & PL) for insurance companies, captives, RRGs, and other risk takers.
  • We know the team at Quadrant well and are excited to take this next step in working together.”
    Jillian Harris, Quadrant President, added, “Quadrant and Verve have developed a longstanding successful relationship that has continued to evolve.
  • For over 20 years Quadrant has specialized in professional liability for insurance companies, captives, RRGs, other risk takers (ACPRO) and insurance retailers, wholesalers, MGAs, reinsurance intermediaries (ABPRO) and more.

BRP Group, Inc. and Nasdaq’s Third Annual Directors and Officers (D&O) Benchmarking Report Includes Key Findings on Cyber Liability in this Year’s Edition

Retrieved on: 
Mercredi, avril 17, 2024

BRP Group, Inc. (NASDAQ: BRP) (“BRP Group”), an independent insurance distribution firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced its third annual Directors and Officers (D&O) & Cyber Benchmarking Report.

Key Points: 
  • BRP Group, Inc. (NASDAQ: BRP) (“BRP Group”), an independent insurance distribution firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced its third annual Directors and Officers (D&O) & Cyber Benchmarking Report.
  • More than 320 public companies participated in this year’s survey, conducted in collaboration with Nasdaq, Inc. (“Nasdaq”).
  • Participating companies provided key policy information regarding their D&O and Cyber Liability insurance coverages.
  • In addition, 58 percent of companies reported seeing a fairly flat Cyber Liability renewal (+/- 10 percent).

Flow Specialty Emerges from Capitola Insurance Rebrand with New Leadership and Enhanced Capabilities

Retrieved on: 
Mercredi, avril 24, 2024

MOUNTAIN VIEW, Calif., April 24, 2024 /PRNewswire-PRWeb/ -- Today, the venture-backed Capitola Insurance has been newly rebranded to Flow Specialty , setting a new standard in the specialty wholesale insurance market.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 24, 2024 /PRNewswire-PRWeb/ -- Today, the venture-backed Capitola Insurance has been newly rebranded to Flow Specialty , setting a new standard in the specialty wholesale insurance market.
  • Integrating human expertise with advanced artificial intelligence (AI), Flow Specialty offers faster quotes, transparent communication, and reduced costs, providing unmatched service and access to premier markets.
  • "Our vision is clear - to transform the wholesale brokerage experience," said Sivan Iram, CEO of Flow.
  • Alongside the strategic rebrand, Flow welcomes David Derigiotis to the team as its new President of Brokerage and Head of Insurance.

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Retrieved on: 
Mardi, avril 2, 2024

MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • The latter clearance was significant since there are no drugs specifically approved to treat early stages I and II of cSCC.
  • As of February, the first two patients in our first cohort have completed treatment with PH-762 with no reported adverse events.
  • In 2023 we implemented a cost rationalization program driven by our transition from discovery research to product development.
  • At December 31, 2023 we had cash of $8.5 million as compared with $11.8 million at December 31, 2022.

Enthusiast Gaming Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Lundi, avril 1, 2024

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three (“Q4 2023”) and 12 months ended December 31, 2023 (“FY 2023”).

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three (“Q4 2023”) and 12 months ended December 31, 2023 (“FY 2023”).
  • “We are moving swiftly to simplify and streamline our business in order to improve financial performance,” commented Adrian Montgomery, Board Chair and interim CEO of Enthusiast Gaming.
  • Direct Sales (included in revenue) increased by 3% to $13.2 million in Q4 2023 compared to $12.8 million in Q4 2022.
  • Adjusted EBITDA loss was $3.0 million in Q4 2023 compared to an Adjusted EBITDA loss of $5.2 million in Q4 2022.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Lundi, avril 1, 2024

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.